Please provide your email address to receive an email when new articles are posted on . The FDA has approved Linzess, the first therapy for pediatric functional constipation in patients aged 6 to 17 ...

FDA has announced it has approved Linzess (linaclotide) to treat chronic idiopathic constipation and to treat irritable bowel syndrome with constipation in adults, according to a news release. Linzess ...

The outlook assumes net sales for Linzess will be between $1.125 billion and $1.175 billion in FY2026. ・U.S. FDA had approved ...

The FDA has approved linaclotide (Linzess) for children aged 7 years or older with irritable bowel syndrome with constipation (IBS-C), making it the first approved treatment for pediatric IBS-C. The ...

The US Food and Drug Administration has expanded its approval of Ironwood Pharmaceuticals' (NASDAQ:IRWD) drug Linzess to include the treatment of functional constipation in children and teens. Linzess ...

Please provide your email address to receive an email when new articles are posted on . AbbVie announced that it has submitted a supplemental new drug application for Linzess for the treatment of ...

Shares of Ironwood Pharmaceuticals IRWD were up 26.7% on Jan. 2 after the company announced upbeat revenue guidance for 2026.

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that The American Journal of Gastroenterology – the official journal of The ...

– Reiterates 2025 guidance of LINZESS U.S. net sales of $800-$850 million and total Ironwood revenue of $260-290 million – – LINZESS (Iinaclotide) EUTRx prescription demand growth in Q1 2025 of 8% ...